本文選題：伏立康唑 + 血液病��； 參考：《中華醫(yī)院感染學(xué)雜志》2017年11期

【摘要】：目的觀察伏立康唑?qū)ρ翰『喜⒎尾壳忠u性真菌感染的二級(jí)防護(hù)的療效。方法選取醫(yī)院血液科2011年1月-2016年4月收治52例惡性血液病患者,分為觀察組與對(duì)照組,各26例,全部患者在化療藥物基礎(chǔ)上,根據(jù)患者發(fā)病情況使用細(xì)胞集落因子、止血藥物、常規(guī)抗真菌藥物等支持藥物治療,觀察組在上述治療基礎(chǔ)之上采用伏立康唑進(jìn)行二級(jí)預(yù)防,治療結(jié)束后觀察兩組患者預(yù)防成功率及不良反應(yīng),并比較兩組患者干擾素伽瑪(IFN-γ)及白介素-10(IL-10)表達(dá)水平。結(jié)果觀察組患者預(yù)防成功率為86.96%,顯著高于對(duì)照組61.90%,差異有統(tǒng)計(jì)學(xué)意義(P0.05);治療前,兩組患者IFN-γ、IL-10表達(dá)水平相當(dāng),差異無(wú)統(tǒng)計(jì)學(xué)意義;治療后,觀察組患者IFN-γ表達(dá)水平高于對(duì)照組,IL-10表達(dá)水平低于對(duì)照組,組間比較差異有統(tǒng)計(jì)學(xué)意義(P0.05);兩組患者不良反應(yīng)輕微,經(jīng)對(duì)癥治療或停藥后均予緩解,觀察組患者總不良反應(yīng)發(fā)生率為39.13%,對(duì)照組為9.52%,差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論伏立康唑用于血液病侵襲性真菌感染的預(yù)防有效且安全,療效確切,耐受性較好,值得臨床推廣應(yīng)用。
[Abstract]:Objective to observe the secondary protective effect of Volconazole on pulmonary invasive fungal infection in patients with hematologic diseases. Methods from January 2011 to April 2016, 52 patients with malignant hematological diseases were divided into two groups: the observation group and the control group. All patients were treated with cytokines on the basis of chemotherapeutic drugs. Hemostatic drugs, routine antifungal drugs and other supportive drugs were used to treat the patients in the observation group. The patients in the observation group were treated with voriconazole for secondary prevention on the basis of the above treatment. After the treatment, the success rate of prevention and the adverse reactions of the two groups were observed. The expression levels of interferon gamma (IFN- 緯) and interleukin-10 (IL-10) were compared between the two groups. Results the successful rate of prevention in the observation group was 86.96, which was significantly higher than that in the control group (61.90), the difference was statistically significant (P 0.05), the expression of IFN- 緯 IL-10 in the two groups was similar before treatment, and there was no significant difference between the two groups after treatment. The level of IFN- 緯 expression in the observation group was higher than that in the control group, and the level of IL-10 was lower than that in the control group, and the difference between the two groups was statistically significant (P 0.05). The incidence of total adverse reactions was 39.13 in the observation group and 9.52 in the control group. Conclusion Volconazole is effective and safe in the prevention of invasive fungal infection in hematological diseases.
【作者單位】： 寧波市奉化區(qū)人民醫(yī)院藥劑科;寧波市奉化區(qū)人民醫(yī)院血液腫瘤科;
【基金】：浙江省醫(yī)藥衛(wèi)生一般研究計(jì)劃基金資助項(xiàng)目(2016KYA016)
【分類號(hào)】：R519;R733

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 熊慧華;余忠貞;石磊;楊林;于世英;王波涌;;伏立康唑治療惡性腫瘤合并侵襲性真菌感染的臨床觀察[J];臨床內(nèi)科雜志;2008年10期

2 張振清;;伏立康唑及氟康唑治療新型隱球菌腦膜炎8例效果比較[J];齊魯護(hù)理雜志;2009年19期

3 林瑞祥;張洪紅;;伏立康唑治療血液病并發(fā)肺部侵襲性真菌感染13例[J];中國(guó)實(shí)用醫(yī)藥;2011年07期

4 秦利人;;103株酵母樣真菌對(duì)伏立康唑、氟康唑的敏感性觀察[J];山東醫(yī)藥;2011年34期

5 沈業(yè)周;楊小鋼;郝定績(jī);;伏立康唑治療淡水淹溺后合并肺部侵襲性真菌感染的臨床分析[J];現(xiàn)代實(shí)用醫(yī)學(xué);2012年01期

6 劉加福;盧彥祥;秦小奉;;伏立康唑序貫治療24例糖尿病合并侵襲性肺曲霉菌病的臨床觀察[J];中國(guó)醫(yī)藥指南;2013年16期

7 陳麗金;婁艷;傅衛(wèi)軍;趙波;;伏立康唑治療1例播散性馬爾尼菲青霉菌病[J];中國(guó)醫(yī)院藥學(xué)雜志;2014年10期

8 李雙燕;溫江麗;武淑萍;;伏立康唑治療老年肺部真菌感染34例分析[J];人民軍醫(yī);2010年10期

9 邢利;苗書(shū)齋;曲青山;蔣欣;李玉華;胡俊杰;;伏立康唑在腎移植術(shù)后侵襲性肺曲霉菌病中的應(yīng)用[J];中華醫(yī)院感染學(xué)雜志;2012年19期

10 湯明;;氟康唑與伏立康唑治療真菌感染性肺炎的療效比較[J];西北藥學(xué)雜志;2014年03期

相關(guān)會(huì)議論文 前5條

1 金哲;;伏立康唑治療變應(yīng)性支氣管肺曲霉病一例[A];中華醫(yī)學(xué)會(huì)呼吸病學(xué)年會(huì)——2013第十四次全國(guó)呼吸病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2013年

2 翁麗燕;何偉珍;;伏立康唑的臨床應(yīng)用分析[A];2011年浙江省醫(yī)學(xué)會(huì)臨床藥學(xué)分會(huì)學(xué)術(shù)年會(huì)論文匯編[C];2011年

3 翁麗燕;何偉珍;;伏立康唑的臨床應(yīng)用分析[A];2012年浙江省醫(yī)學(xué)會(huì)臨床藥學(xué)學(xué)術(shù)年會(huì)暨醫(yī)院藥事管理質(zhì)控中心、臨床藥學(xué)分會(huì)十周年慶典大會(huì)論文集[C];2012年

4 陳麗金;婁艷;傅衛(wèi)軍;趙波;;伏立康唑治療一例播散性馬爾尼菲青霉菌病[A];2014年廣東省藥師周大會(huì)論文集[C];2014年

5 劉偉;孫毅;劉偉霞;陳偉;萬(wàn)U，

本文編號(hào)：1791444